Literature DB >> 29036300

Bayesian hierarchical modeling based on multisource exchangeability.

Alexander M Kaizer1, Joseph S Koopmeiners2, Brian P Hobbs2.   

Abstract

Bayesian hierarchical models produce shrinkage estimators that can be used as the basis for integrating supplementary data into the analysis of a primary data source. Established approaches should be considered limited, however, because posterior estimation either requires prespecification of a shrinkage weight for each source or relies on the data to inform a single parameter, which determines the extent of influence or shrinkage from all sources, risking considerable bias or minimal borrowing. We introduce multisource exchangeability models (MEMs), a general Bayesian approach for integrating multiple, potentially non-exchangeable, supplemental data sources into the analysis of a primary data source. Our proposed modeling framework yields source-specific smoothing parameters that can be estimated in the presence of the data to facilitate a dynamic multi-resolution smoothed estimator that is asymptotically consistent while reducing the dimensionality of the prior space. When compared with competing Bayesian hierarchical modeling strategies, we demonstrate that MEMs achieve approximately 2.2 times larger median effective supplemental sample size when the supplemental data sources are exchangeable as well as a 56% reduction in bias when there is heterogeneity among the supplemental sources. We illustrate the application of MEMs using a recently completed randomized trial of very low nicotine content cigarettes, which resulted in a 30% improvement in efficiency compared with the standard analysis.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29036300      PMCID: PMC5862286          DOI: 10.1093/biostatistics/kxx031

Source DB:  PubMed          Journal:  Biostatistics        ISSN: 1465-4644            Impact factor:   5.899


  19 in total

1.  Bayesian methods for cluster randomized trials with continuous responses.

Authors:  D J Spiegelhalter
Journal:  Stat Med       Date:  2001-02-15       Impact factor: 2.373

2.  Meta-analysis of heterogeneous clinical trials: an empirical example.

Authors:  Suhail A R Doi; Jan J Barendregt; Ellen L Mozurkewich
Journal:  Contemp Clin Trials       Date:  2010-12-13       Impact factor: 2.226

3.  Randomized Trial of Reduced-Nicotine Standards for Cigarettes.

Authors:  Eric C Donny; Rachel L Denlinger; Jennifer W Tidey; Joseph S Koopmeiners; Neal L Benowitz; Ryan G Vandrey; Mustafa al'Absi; Steven G Carmella; Paul M Cinciripini; Sarah S Dermody; David J Drobes; Stephen S Hecht; Joni Jensen; Tonya Lane; Chap T Le; F Joseph McClernon; Ivan D Montoya; Sharon E Murphy; Jason D Robinson; Maxine L Stitzer; Andrew A Strasser; Hilary Tindle; Dorothy K Hatsukami
Journal:  N Engl J Med       Date:  2015-10       Impact factor: 91.245

4.  Bayesian sample size for exploratory clinical trials incorporating historical data.

Authors:  John Whitehead; Elsa Valdés-Márquez; Patrick Johnson; Gordon Graham
Journal:  Stat Med       Date:  2008-06-15       Impact factor: 2.373

5.  Determining the effective sample size of a parametric prior.

Authors:  Satoshi Morita; Peter F Thall; Peter Müller
Journal:  Biometrics       Date:  2007-08-30       Impact factor: 2.571

Review 6.  Incorporation of historical data in the analysis of randomized therapeutic trials.

Authors:  Charlotte Rietbergen; Irene Klugkist; Kristel J M Janssen; Karel G M Moons; Herbert J A Hoijtink
Journal:  Contemp Clin Trials       Date:  2011-06-25       Impact factor: 2.226

7.  A Bayesian approach to randomized controlled trials in children utilizing information from adults: the case of Guillain-Barré syndrome.

Authors:  Steven N Goodman; John T Sladky
Journal:  Clin Trials       Date:  2005       Impact factor: 2.486

8.  Commensurate Priors for Incorporating Historical Information in Clinical Trials Using General and Generalized Linear Models.

Authors:  Brian P Hobbs; Daniel J Sargent; Bradley P Carlin
Journal:  Bayesian Anal       Date:  2012-08-28       Impact factor: 3.728

9.  Semiparametric Bayesian commensurate survival model for post-market medical device surveillance with non-exchangeable historical data.

Authors:  Thomas A Murray; Brian P Hobbs; Theodore C Lystig; Bradley P Carlin
Journal:  Biometrics       Date:  2013-12-05       Impact factor: 2.571

10.  Terminated Trials in the ClinicalTrials.gov Results Database: Evaluation of Availability of Primary Outcome Data and Reasons for Termination.

Authors:  Rebecca J Williams; Tony Tse; Katelyn DiPiazza; Deborah A Zarin
Journal:  PLoS One       Date:  2015-05-26       Impact factor: 3.240

View more
  9 in total

Review 1.  Histology-agnostic drug development - considering issues beyond the tissue.

Authors:  Roberto Carmagnani Pestana; Shiraj Sen; Brian P Hobbs; David S Hong
Journal:  Nat Rev Clin Oncol       Date:  2020-06-11       Impact factor: 66.675

2.  Design and Evaluation of an External Control Arm Using Prior Clinical Trials and Real-World Data.

Authors:  Steffen Ventz; Albert Lai; Timothy F Cloughesy; Patrick Y Wen; Lorenzo Trippa; Brian M Alexander
Journal:  Clin Cancer Res       Date:  2019-06-07       Impact factor: 12.531

3.  A group-sequential randomized trial design utilizing supplemental trial data.

Authors:  Ales Kotalik; David M Vock; Brian P Hobbs; Joseph S Koopmeiners
Journal:  Stat Med       Date:  2021-11-09       Impact factor: 2.373

4.  BRIDGING RANDOMIZED CONTROLLED TRIALS AND SINGLE-ARM TRIALS USING COMMENSURATE PRIORS IN ARM-BASED NETWORK META-ANALYSIS.

Authors:  Zhenxun Wang; Lifeng Lin; Thomas Murray; James S Hodges; Haitao Chu
Journal:  Ann Appl Stat       Date:  2021-12-21       Impact factor: 1.959

5.  Dynamic borrowing in the presence of treatment effect heterogeneity.

Authors:  Ales Kotalik; David M Vock; Eric C Donny; Dorothy K Hatsukami; Joseph S Koopmeiners
Journal:  Biostatistics       Date:  2021-10-13       Impact factor: 5.899

Review 6.  Seamless Designs: Current Practice and Considerations for Early-Phase Drug Development in Oncology.

Authors:  Brian P Hobbs; Pedro C Barata; Yada Kanjanapan; Channing J Paller; Jane Perlmutter; Gregory R Pond; Tatiana M Prowell; Eric H Rubin; Lesley K Seymour; Nolan A Wages; Timothy A Yap; David Feltquate; Elizabeth Garrett-Mayer; William Grossman; David S Hong; S Percy Ivy; Lillian L Siu; Steven A Reeves; Gary L Rosner
Journal:  J Natl Cancer Inst       Date:  2019-02-01       Impact factor: 13.506

7.  Bayesian hierarchical meta-analytic methods for modeling surrogate relationships that vary across treatment classes using aggregate data.

Authors:  Tasos Papanikos; John R Thompson; Keith R Abrams; Nicolas Städler; Oriana Ciani; Rod Taylor; Sylwia Bujkiewicz
Journal:  Stat Med       Date:  2020-01-28       Impact factor: 2.373

Review 8.  Comparative Study of Bayesian Information Borrowing Methods in Oncology Clinical Trials.

Authors:  Liwen Su; Xin Chen; Jingyi Zhang; Fangrong Yan
Journal:  JCO Precis Oncol       Date:  2022-03

9.  Bayesian and frequentist approaches to sequential monitoring for futility in oncology basket trials: A comparison of Simon's two-stage design and Bayesian predictive probability monitoring with information sharing across baskets.

Authors:  Alexander Kaizer; Emily Zabor; Lei Nie; Brian Hobbs
Journal:  PLoS One       Date:  2022-08-02       Impact factor: 3.752

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.